US Patent Application 20100143349 - HUMANIZED ANTI-RAGE ANTIBODY
Inventors
AssigneeUS Classes424/133.1, Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)530/387.3, Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)530/389.1, Polyclonal antibody or immunogloblin of identified binding specificity536/23.53ImmunoglobulinAttorney, Agent or FirmInternational ClassesA61K 39/395C07K 16/28 C07H 21/04 A61P 31/04 A61P 35/00 A61P 29/00 A61P 19/02 A61P 1/00 A61P 9/00 A61P 15/00 A61P 25/00 A61P 27/02 A61P 3/10 Abstract textCompositions comprising antigen binding polypeptides that bind specifically to Receptor For Advanced Glycation End-product (RAGE) and comprises: one or more complementarity determining regions (CDRs) with improved binding efficiency over a parental monoclonal antibody to RAGE are described. Antibodies containing the CDR's and methods of treating a RAGE-related disease or disorder comprising administering to the subject a therapeutically effective amount of the compositions of the invention are also provided. |
| ||||||||||||||
